{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-003114","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.518922+00:00","generated_at":"2026-05-23T02:31:11.635522+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioNexus Gene Lab regains Nasdaq minimum bid price compliance, avoids delisting","bullets":["Received Nasdaq Panel confirmation on Apr 30, 2025, that BGLC met $1.00 minimum bid price rule.","Stock closed at $1.00+ for required consecutive business days as of Apr 23, 2025.","Company plans to expand RNA diagnostics and specialty chemicals via Chemrex and MRNA Scientific.","Appointed new independent board members and formed internal audit function to strengthen governance."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-003114","json":"https://secwatch.observer/filing/0001477932-25-003114.json","markdown":"https://secwatch.observer/filing/0001477932-25-003114.md","text":"https://secwatch.observer/filing/0001477932-25-003114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225003114/0001477932-25-003114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225003114/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:31:11.635522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"963a67689cdeed0aa737a6414297ef0a71611c1e","claim":"BioNexus Gene Lab Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"April 30, 2025, BioNexus Gene Lab Corp. (the “Company”) received a formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The Company was previously notified of non-compliance with the Bid Price Rule and appeared before the Panel pursuant to Docket No. NQ 7050C-24. As of April 23, 2025, the Company’s common stock had maintained a closing bid price of $1.00 or greater for the requisite number of consecutive business day","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225003114/0001477932-25-003114-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}